Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PolyPid Ltd PYPD

Healthcare Biotechnology
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Recent & Breaking News (NDAQ:PYPD)

PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

GlobeNewswire June 6, 2022

PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

GlobeNewswire June 2, 2022

PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

GlobeNewswire June 1, 2022

PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire May 31, 2022

PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

GlobeNewswire May 23, 2022

PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 11, 2022

PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022

GlobeNewswire April 27, 2022

PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

GlobeNewswire April 25, 2022

PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting

GlobeNewswire April 12, 2022

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

GlobeNewswire April 6, 2022

PolyPid to Deliver Poster Presentation at SAGES 2022

GlobeNewswire March 8, 2022

PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

GlobeNewswire March 2, 2022

PolyPid to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 1, 2022

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

GlobeNewswire February 9, 2022

PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022

GlobeNewswire January 26, 2022

PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

GlobeNewswire January 4, 2022

PolyPid Announces Planned CEO Transition

GlobeNewswire January 3, 2022

PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

GlobeNewswire November 18, 2021

PolyPid Appoints New Oncology Advisory Board Member

GlobeNewswire November 16, 2021

PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2021